More recently, investigations of PD, ALS, and MS as well brain trauma, neonatal hypoxia, and glioblastoma have reinforced the interest for 24HC as a biomarker of disease progression and highlighted the role of CYP46A1 in this process or even disease genesis. The gene discussed is CYP46A1; the disease is myeloid sarcoma.